Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Health Plans’ Response To Claritin OTC Needs Monitoring For Collusion – WLF

Executive Summary

The Washington Legal Foundation will be monitoring formulary decisions by managed care organizations for evidence of collusion following approval of OTC Claritin

You may also be interested in...



FTC’s Next Chairman Expected To Be Health Care Antitrust Expert Majoras

President Bush intends to nominate health care antitrust attorney Deborah Majoras as Federal Trade Commission chairman

FTC’s Next Chairman Expected To Be Health Care Antitrust Expert Majoras

President Bush intends to nominate health care antitrust attorney Deborah Majoras as Federal Trade Commission chairman

Disclosure Of Drug Costs By Manufacturers To Be Explored In FTC Hearings

Drug companies' disclosure of Rx costs will be considered by the Federal Trade Commission in a series of hearings set to begin in February

UsernamePublicRestriction

Register

LL1129367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel